Biobanking and Biomarker Validation (BBV) Core
Biobanking and Biomarker Validation (BBV) Core
批准号:
10582682
负责人:
ANDREW K. GODWIN
金额:
$24.2万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-02-15 至 2024-04-14
关键词:
AccreditationAreaB-LymphocytesBRAF geneBenignBiological AssayBiological Specimen BanksBiomedical EngineeringBiomedical ResearchBloodBlood specimenBody FluidsCLIA certifiedCancer CenterCaringCell LineCellsCenters of Research ExcellenceClinicalClinical ResearchClinical TrialsCollectionCommunitiesCore FacilityCustomDNADevelopmentDiagnosisDiseaseEnsureEnzyme-Linked Immunosorbent AssayEpidermal Growth Factor ReceptorEvaluationEventFLT3 geneFacultyFamily history ofFosteringFresh TissueFundingFutureGenesGenomic DNAGenomicsGoalsHealthcareHistologyHumanImmunoassayImmunohistochemistryIndividualInformed ConsentInfrastructureInstitutionInterdisciplinary StudyInterventionIrrigationJAK2 geneKRAS2 geneKansasLaboratoriesLengthLiquid substanceMalignant NeoplasmsMeasurementMedical centerMessenger RNAMethylationMicroRNAsMicrosatellite InstabilityMissionMolecularMolecular Diagnostic TestingMutation AnalysisNeeds AssessmentNoseNucleic AcidsParticipantPathologicPatientsPlasmaPleuralPopulationProteinsResearchResearch PersonnelResidual NeoplasmResourcesRoleSalivaSamplingScienceSerumServicesSomatic MutationSpecimenT cell clonalityTechnical ExpertiseTestingTissue StainsTissuesUniversitiesUrineWestern BlottingWhole BloodWorkactive dutybasebcr-abl Fusion Proteinsbiobankbiomarker developmentbiomarker discoverybiomarker validationcell free DNAcost effectivedesignexosomeextracellular vesiclesgenetic signaturehuman leukocyte antigen testingimprovedimproved outcomeinnovationlifestyle factorsmalignant breast neoplasmmolecular diagnosticsmolecular oncologynext generation sequencingpersonalized carepre-clinicalprecision medicineprognosticprogramspromoterrelative costrepositoryresearch clinical testingresearch studysuccesstelomere
中文摘要
点击翻译按钮获取中文摘要
英文摘要
COBRE Kansas Institute for Precision Medicine (KIPM) – “Biobanking and Biomarker Validation Core”
ABSTRACT
The overall objective of the “Kansas Institute for Precision Medicine” (KIPM) COBRE at the University of Kansas
Medical Center (KUMC) is to advance the customization of healthcare through promoting innovative scientific
discoveries. We have entered the era of Precision Medicine, an initiative recently announced as part of the 21st
Century Cures Act, which is focused on using the molecular basis of diseases to better match patients with the
appropriate therapies and care resulting in improved outcomes. To advance this mission, we have established
the Biobanking and Biomarker Validation (BBV) Core, which combines exceptional expertise and essential
resources within established infrastructure, i.e., Biospecimen Repository Core Facility (BRCF), the Biomarker
Discovery Laboratory (BDL), and the Clinical Molecular Oncology Laboratory (CMOL). Access to the BBV core
will strengthen the biomedical research capacity of our COBRE faculty by enhancing their research base and
infrastructure capacities. To advance precision medicine research within this COBRE, the BBV core will 1)
Provide centralized and uniform collections, processing, and storage of tissue and bodily fluids and tissue-related
histology services; 2) provide integral and comprehensive protein and nucleic acid isolation, quantitation, and
molecular characterization services; and 3) provide fully customizable molecular testing and genomic-based
sequencing services. The BBV core is designed to centralize these essential services that will in turn provide
support to the KIPM COBRE faculty, pilot grantees, and researchers within our region and beyond. Given the
level of sophistication of the materials and services required for the range of studies proposed within the KIPM
COBRE, a highly integrated BBV core is not only cost effective but an absolute necessity. The BBV core
eliminates redundant infrastructure and expense required for each researcher to develop their own capabilities
or to search for the necessary research expertise. The BBV core will enable multiple COBRE faculty and future
pilot grantees, access to state-of-the-art facilities and laboratory expertise, thereby further reducing the relative
cost of their studies. Furthermore, the BBV core will continue to provide in-kind technical staff-support and
banking resources, which help the KIPM COBRE faculty to more effectively utilize their funding, both institutional
startup and COBRE support. The success of the BBV core and ultimately the COBRE faculty is essential to
advancing the mission of the KIPM to advance the customization of healthcare through promoting innovative
scientific discoveries.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Kansas Institute for Precision Medicine : Zeiss Axioscan 7
-
批准号:10610667
-
项目类别:
-
资助金额:$20.97万
-
财政年份:2022
-
负责人:ANDREW K. GODWIN
-
依托单位:
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
-
批准号:10526715
-
项目类别:
-
资助金额:$16.08万
-
财政年份:2021
-
负责人:ANDREW K. GODWIN
-
依托单位:
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
-
批准号:10621734
-
项目类别:
-
资助金额:$59.3万
-
财政年份:2021
-
负责人:ANDREW K. GODWIN
-
依托单位:
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
-
批准号:10373086
-
项目类别:
-
资助金额:$62.69万
-
财政年份:2021
-
负责人:ANDREW K. GODWIN
-
依托单位:
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
-
批准号:10199594
-
项目类别:
-
资助金额:$65.55万
-
财政年份:2021
-
负责人:ANDREW K. GODWIN
-
依托单位:
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancer
-
批准号:10307656
-
项目类别:
-
资助金额:$19.59万
-
财政年份:2021
-
负责人:ANDREW K. GODWIN
-
依托单位:
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
-
批准号:10737826
-
项目类别:
-
资助金额:$15.79万
-
财政年份:2021
-
负责人:ANDREW K. GODWIN
-
依托单位:
The Kansas Institute for Precision Medicine
-
批准号:10582647
-
项目类别:
-
资助金额:$224.19万
-
财政年份:2019
-
负责人:ANDREW K. GODWIN
-
依托单位:
The Kansas Institute for Precision Medicine: IsoPlexis IsoSpark
-
批准号:10806784
-
项目类别:
-
资助金额:$16.48万
-
财政年份:2019
-
负责人:ANDREW K. GODWIN
-
依托单位:
Administrative Core
-
批准号:10867199
-
项目类别:
-
资助金额:$16.48万
-
财政年份:2019
-
负责人:ANDREW K. GODWIN
-
依托单位:
Administrative Core
-
批准号:10582668
-
项目类别:
-
资助金额:$94.92万
-
财政年份:2019
-
负责人:ANDREW K. GODWIN
-
依托单位:
Administrative Core
-
批准号:10115107
-
项目类别:
-
资助金额:$49.34万
-
财政年份:2019
-
负责人:ANDREW K. GODWIN
-
依托单位:
Biobanking and Biomarker Validation (BBV) Core
-
批准号:10115115
-
项目类别:
-
资助金额:$22.21万
-
财政年份:2019
-
负责人:ANDREW K. GODWIN
-
依托单位:
Developmental Funds Core
-
批准号:10493591
-
项目类别:
-
资助金额:$68.75万
-
财政年份:2012
-
负责人:ANDREW K. GODWIN
-
依托单位:
Biospecimen Shared Resource
-
批准号:10493595
-
项目类别:
-
资助金额:$17.97万
-
财政年份:2012
-
负责人:ANDREW K. GODWIN
-
依托单位:
Biospecimen Shared Resource
-
批准号:9975733
-
项目类别:
-
资助金额:$15.19万
-
财政年份:2012
-
负责人:ANDREW K. GODWIN
-
依托单位:
Developmental Funds Core
-
批准号:10671721
-
项目类别:
-
资助金额:$66.73万
-
财政年份:2012
-
负责人:ANDREW K. GODWIN
-
依托单位:
Biospecimen Shared Resource
-
批准号:10671734
-
项目类别:
-
资助金额:$18.13万
-
财政年份:2012
-
负责人:ANDREW K. GODWIN
-
依托单位:
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer
-
批准号:8444503
-
项目类别:
-
资助金额:$30.54万
-
财政年份:2010
-
负责人:ANDREW K. GODWIN
-
依托单位:
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer
-
批准号:8730322
-
项目类别:
-
资助金额:$5.8万
-
财政年份:2010
-
负责人:ANDREW K. GODWIN
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: